|
Company
Profile
"GeneExpression
Systems has been incorporated in the Commonwealth of Massachusetts
in the year of 1999 by Harvard and MIT trained scientists”
GES develops,
applies and markets qualitative and quantitative differential
gene profiling technology for down stream study of gene expression
and regulation, diagnostic, predictive toxicology and therapeutic
purposes. We are a molecular biology contract research organization
providing reagents and services to the researchers in academic,
biotechnology and pharmaceutical industries in the emerging
business segments of molecular cell biology, genomics, proteomics,
and bioinformatics. GES develops and commercializes proprietary
gene expression kits, services and technologies to accelerate
and enhance the discovery of new markers.
We are developing
new tools for monitoring the “Differential Gene ProfilingTM
“ (DGP) to create a new “functional genomics”
platform, and to maintain proprietary databases for medically
(disease) relevant genes. In addition, the company intends
to perform gene discovery research in the areas of cancer
(colon, lung, breast) and inflammatory bowel disease (Ulcerative
colitis) using state-of-the art gene expression technology
platforms.
Apart
from this gene discovery model GeneExpression Systems, Inc.
collaborates with international companies to market compatible
technology/instruments/products in the US market.
Our
Mission
Leadership in applying basic
biology techniques and informatics tools in the fields of
PharmacoGenomics, ToxicoGenomics, Proteomics and Clinical
Genomics to create proprietary high value solutions in Applied
Medical Sciences and beyond.
Our commitment is to discover
gene-markers for the early diagnosis of colon cancer, lung
cancer and inflammatory bowel diseases utilizing the state-of-the
art gene expression technology.
Our core competency is the
application of differential gene profiling (DGP) strategy
for disease diagnosis.
 |
